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Abstract 
Background: The World Health Organization (WHO) recommends injectable artesunate given either intravenously 
or by the intramuscular route for definitive treatment for severe malaria and recommends a single intramuscular 
dose of intramuscular artesunate or intramuscular artemether or intramuscular quinine, in that order of preference 
as pre-referral treatment when definitive treatment is not possible. Where intramuscular injections are not available, 
children under 6 years may be administered a single dose of rectal artesunate. Although the current malaria treat-
ment guidelines in Ethiopia recommend intra-rectal artesunate or alternatively intramuscular artemether or intramus-
cular quinine as pre-referral treatment for severe malaria at the health posts, there are currently no WHO prequalified 
suppliers of intra-rectal artesunate and when available, its use is limited to children under 6 years of age leaving a gap 
for the older age groups. Intramuscular artesunate is not part of the drugs recommended for pre-referral treatment 
in Ethiopia. This study assessed the perspectives of health workers, and policy-makers on the use of intramuscular 
artesunate as a pre-referral and definitive treatment for severe malaria at the health post level.
Methods: In-depth interviews were held with 101 individuals including health workers, malaria focal persons, and 
Regional Health Bureaus from Oromia and southern nations, nationalities, and peoples’ region, as well as participants 
from the Federal Ministry of Health and development partners. An interview guide was used in the data collection 
and thematic content analysis was employed for analysis.
Results: Key findings from this study are: (1) provision of intramuscular artesunate as pre-referral and definitive 
treatment for severe malaria at health posts could be lifesaving; (2) with adequate training, and provision of facilities 
including beds, health posts can provide definitive treatment for severe malaria using intramuscular artesunate where 
referral is delayed or not possible; (3) health workers at health centres and hospitals frequently use the intravenous 
route because it allows for co-administration of other drugs, but they find the intramuscular route easier to use at 
the health post level; (4) the reasons commonly cited against the management of severe malaria using intramuscular 
artesunate at health post level were: lack of capacity to manage complications and fear of irrational drug use; (5) use 
of intramuscular artesunate at health post level will require evidence on safety and feasibility before policy shift.
Conclusion: From the perspective of health workers, use of intramuscular artesunate as pre-referral treatment of 
severe malaria cases at the health post is possible but dependent on training and availability of skilled workers. Use of 
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Background
Malaria is endemic throughout most of the tropics, with 
approximately 214 million cases and 438,000 deaths 
reported in 2015 alone [1]. About 88  % of cases and 
90 % of deaths occur in the World Health Organization 
(WHO) African region, and 70  % of deaths are among 
children under 5 years of age [1]. In endemic areas, young 
children and pregnant women are at high risk for severe 
malaria [2, 3].
Severe malaria is a life threatening medical emergency 
that requires prompt and effective treatment to prevent 
death [1, 4]. Death from severe malaria often occurs 
within hours of admission to health facilities due to prob-
lems with patients accessing treatment in a timely man-
ner. It is essential that therapeutic concentrations of a 
highly effective anti-malarial drug are achieved as soon as 
possible, and that there is access to curative treatments as 
close as possible to where the patient lives. Compared to 
most other malaria-endemic countries in Africa, malaria 
prevalence is relatively low in Ethiopia with the parasite 
prevalence estimated at 0.5 % in the recently concluded 
malaria indicator survey [5]. Ethiopia was ranked 10th 
in terms of estimated incidence of malaria in East Africa 
in 2015 [1]. However, despite a low prevalence, malaria 
is a major public health problem and is one of the four 
leading cause of illness in children under 5 years of age in 
Ethiopia [6].
The current WHO recommendation is to give a par-
enteral antimalarial drug to treat severe malaria for a 
minimum of 24  h irrespective of the patient’s ability to 
tolerate oral medication, before giving the oral follow-
up artemisinin-based combination therapy (ACT) [7]. 
The risk of death in severe malaria is greatest in the first 
24 h, yet the transit time between referral and arrival at 
health facilities with access to parenteral treatments is 
usually long. Mortality in untreated severe malaria cases 
approaches 100  % [7], and especially in areas of low, 
unstable malaria transmission [8]. Ethiopia has unstable 
malaria transmission and, therefore, epidemics are seri-
ous public health emergencies.
Referral of severely ill patients is faced with many chal-
lenges including lack of transport, long distance to health 
facilities, lack of funds for transport, distances to be cov-
ered, lack of referral slip, poor communication and poor 
road networks [9]. WHO recommends that where com-
plete treatment of severe malaria is not possible patients 
be given single dose of the recommended parenteral 
treatment before referral [7, 10]. It recommends that 
where complete treatment of severe malaria is not possi-
ble but injections are available, adults and children should 
be administered as referral treatment, a single intramus-
cular dose of artesunate or intramuscular artemether or 
intramuscular quinine, in that order of preference before 
referring to an appropriate higher health facility. Where 
intramuscular injections are not available, children 
under 6 years may be administered a single dose of rectal 
artesunate [7].
In developing countries, pre-referral care for severe ill-
nesses such as severe malaria face major challenges due 
to frequent stock-outs or shortages of essential supplies, 
and poorly organized emergency treatment [11, 12]. The 
basic components of severe malaria case management 
are lacking in most health facilities including oxygen and 
blood transfusion [13].
The Ethiopian government is making efforts to increase 
access to care for the entire population. However, in 
many areas access to qualified specialist care is still lim-
ited. The Ethiopian health service is restructured into a 
three tier system: (1) primary health care unit consisting 
of a primary hospitals, health centres and health posts, 
(2) general hospitals, and (3) specialized hospitals (Fig. 1). 
The health posts are managed by two health extension 
workers who are recruited among high school gradu-
ates in local communities, and undergo a 1-year train-
ing program to deliver a package of preventive and basic 
curative services that fall under four main components: 
hygiene and environmental sanitation; family health ser-
vices; disease prevention and control; and health educa-
tion and communication. The health centres are staffed 
by around 20 professionals and provide preventive, cura-
tive, inpatient and ambulatory services, treatment of 
common psychiatric disorders, and dental services. Pri-
mary hospitals are staffed by around 53 professionals and 
provide preventive, curative, inpatient and ambulatory 
services, and emergency surgical services, including cae-
sarean section and blood transfusion. They also serve as 
referral centres for health centres and practical training 
centres for nurses and paramedical health professionals. 
General hospitals are staffed by around 234 persons and 
provide inpatient and ambulatory services. They are also 
referral centres for primary hospitals and training centres 
for health officers, nurses, emergency surgeons and other 
intramuscular artesunate as definitive treatment at health posts was not supported, however, operational research to 
establish its feasibility, safety and efficacy was recommended to guide any implementation of such an intervention.
Keywords: Severe malaria, Intramuscular artesunate, Perspectives, Intra-rectal artesunate, Health post, Health 
extension worker
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categories of health workers. The specialized hospital is 
staffed by around 440 professionals and serves as a refer-
ral centre for the general hospitals and provides inpatient 
services.
The health workforce density in Ethiopia increased 
from 0.84 to 1.3 per 1000 population between 2008 and 
2013 indicating improvement in supply and availability of 
health workers. However, the doctor, health officer, nurse 
and midwife to population ratio is 0.7 per 1000 popula-
tion, far behind the minimum threshold of 2.3 doctor, 
nurse and midwife to 1000 population ratio required to 
ensure high coverage with essential health interventions. 
Nevertheless, the health extension programme has over 
38,000 health extension workers working in more than 
16,000 health posts thereby reaching households with 
essential health packages [14, 15].
In the national strategic plan 2014–2020, Ethiopia 
has a target of 100  % access to effective and affordable 
malaria treatment and to achieve near zero malaria 
deaths by 2020 [6]. This requires improving diagnosis of 
malaria cases using microscopy or using multi-species 
rapid diagnostic tests (RDTs), and providing prompt 
and effective malaria case management at all health 
facilities level in the country. Most malaria cases are first 
seen and treated at health posts and health centre level. 
According to the national malaria treatment guidelines, 
patients arriving at a health post with severe malaria are 
given intrarectal artesunate or intramuscular artemether 
when intrarectal artesunate is unavailable [16]. Unfortu-
nately, there are no prequalified manufacturers for rectal 
artesunate and its use is only recommended for children 
under 6  years [17]. WHO recommends intramuscular 
artesunate for pre-referral treatment [7], but this is not 
currently included in the national policy guidelines in 
Ethiopia [16] to be delivered by health extension workers 
in Ethiopia.
Intravenous injections require cannulation and may be 
beyond the level of skills found at health posts; however, 
intramuscular injections are administered at this level. 
Studies have shown that intramuscular artesunate is rap-
idly absorbed when used for managing severe malaria in 
contrast to artemether which is oil based and absorption 
may be delayed especially in shocked patients [18, 19]. 
Intramuscular and intravenous artesunate have also been 
reported to be equally effective in adults [20] and chil-
dren [21].
In hard to reach areas where referral of severe malaria 
cases is not possible or delayed, the only option left to 
patients and caregivers is to return home and use what-
ever is available within their community, at great danger 
to lives [22]. For these settings could health posts that 
are closer to communities, and where health extension 
workers have been properly trained and equipped pro-
vide pre-referral treatment for severe malaria using intra-
muscular artesunate as recommended by WHO? Could 
they also provide definitive treatment (defined as the 
treatment plan for a disease that has been chosen as the 
best for a patient after all other choices have been consid-
ered) where referral is delayed or not possible, given that 
many already provide intramuscular treatments for other 
conditions? This study sought to explore the perspec-
tives of health workers, and policy makers on the use of 
intramuscular artesunate as a pre-referral and definitive 
treatment for severe malaria at health post level in Ethio-
pia. This will provide valuable information on the policy 




The study was conducted in two regions of Ethiopia, 
southern nations, nationalities, and peoples’ region 
(SNNPR), and Oromia from January to March, 2015. 
Participants were identified from health facilities serv-
ing nine malarious areas of the regions, Zonal offices, 
Regional Health Bureaus, Federal Ministry of Health and 
partners.
Oromia is the most populous region in Ethiopia with 
a total population of 32 million. SNNPR is the 3rd larg-
est regional state with a total population of 18 million 
[6]. SNNPR and Oromia regions have the highest malaria 
burden in Ethiopia [23].
The major health problems of SNNPR and Oromia 
remain largely preventable communicable diseases and 
nutritional disorders. The health system priorities are 
health service delivery at household, community and 
facility level to improve maternal, neonatal, child, ado-
lescent and youth health, nutrition, hygiene and envi-
ronmental health, and to reduce/combat HIV/AIDS, 
Terary level of health 
Secondary level of 
Primary level of health 
Ethiopian Health System Tiers
Fig. 1 Different tiers of the Ethiopia health system and the approxi-
mate population they cover
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tuberculosis and malaria and other communicable and 
non-communicable diseases [15].
Access to care remains a problem especially in rural 
areas where the population is characterized by poverty 
and poor health indicators. The Ethiopian government 
has endeavored to improve access to care by providing 
a community based service provided by health exten-
sion workers who after a year’s training provide compre-
hensive preventive and curative services to these remote 
populations and by equipping health centres with ambu-
lances to provide care for obstetric and other emergen-
cies but referral from health post could be delayed due 
to poor infrastructure or other emergencies. The Ethiopia 
health care tiers are presented in Fig. 1.
Study design
This was a qualitative exploratory study that used in-
depth interviews to collect data on the perspectives of 
health workers, and policy-makers on the use of intra-
muscular artesunate as a pre-referral and definitive treat-
ment for severe malaria at health posts.
Sample size and sampling technique
A total of 101 respondents were interviewed. A list of 
all zones from the two regions regarded high burden by 
the Federal Ministry of Health was used and from this 
list nine zones with the highest burden were selected. 
The selected zones were the following: East Shoa, South 
west Shoa and Jima zone from Oromia region, and 
Gomgofa, Silti, Kembata Tembaro, Halaba, Wolayita and 
Hadiya zones from SNNPR. A zone is an administrative 
area below the region, and includes several districts or 
woredas.
Thirty health facilities from each of the two states 
(Oromia and SNNPR) were purposively selected to be 
included in the study if they had large numbers of severe 
malaria cases reported (according to the routine health 
facility data reports) and if were easily accessible by the 
study team.
Study population
A maximum of two health workers, one health worker 
involved in management of malaria on the day of the 
interview and one manager in the selected health facili-
ties were included in the study. In Oromia state, given 
the busy schedules of the health workers, it was impos-
sible to interview more than one staff at the selected 
facilities, and two of the selected facilities were not open 
on the survey day. In SNNPR, all selected facilities were 
functional and two health workers were interviewed at 
each of the facilities. At two of the facilities in SNNPR, 
the team was able to interview both the severe malaria 
ward manager and well as the health facility manager. 
In addition, the malaria focal persons from the Zonal 
health departments, Regional Health Bureau, Federal 
Ministry of Health, and development partners were also 
included in the study. The number of respondents inter-
viewed within the different categories are presented in 
Table 1.
Data collection
An interview guide was used to collect data from 
respondents. In-depth interviews were conducted by 
twenty research assistants with research experience and 
trained in data collection specifically for this study. The 
interviews were conducted in the local languages. The 
research assistants working in pairs approached the man-
agers and asked permission to conduct the study in the 
health facilities and for guidance on the health workers to 
be interviewed. Informed consent was then sought from 
the health workers to participate in the study. Appoint-
ments were made for interviews with all other partici-
pants at zonal, regional, Federal Ministry of Health and 
development partners. The research assistants took notes 
and audio recordings during the interviews. Supervi-
sion and guidance to the field teams was provided by two 
co-investigators with experience conducting qualitative 
research. Daily supervision of interviewers and checking 
of completed interviews was done to ensure collection of 
accurate and complete data.
Data analysis
Audio-recorded data were transcribed and then trans-
lated from the local languages to Amharic and then into 
English. Senior researchers read the transcripts and iden-
tified emerging themes, and codes. The transcripts were 
then coded using Atlas.ti7 (Atlas.ti GmbH, Berlin) during 
the coding process; more codes were identified and dis-
cussed by the research team. These codes were merged 
into categories and then into themes reflecting the study 
objectives and other emerging issues. Thematic content 
analysis was employed.
Table 1 Respondents selected by category and region
Category Region Total
SNNPR Oromia
Health post staff 30 13 43
Health centre staff 25 10 35
District, zonal and regional staff 4 3 7
Hospital staff 7 5 12
FMOH N/A N/A 1
Partners N/A N/A 3
Total 66 31 101
Page 5 of 10Kefyalew et al. Malar J  (2016) 15:507 
Results
Characteristics of the study population
A total of 101 respondents were interviewed (Table  1). 
Of these, 66 (66.7 %) and 31 (31.3 %) were from SNNPR 
and Oromia regions respectively. The majority (73/101; 
72 %) of the participants worked at various health facili-
ties providing treatment and care for severe malaria 
cases. Other participants were from Zonal and Regional 
health departments or district health offices (7), Health 
Bureau and Federal Ministry of Health (1) and partner 
institutions (3). 63  % of the participants were female, 
while the average age of participants was 28 years (stand-
ard deviation 6.3). 65 % of the participants held either a 
degree in public health or nursing; 27 % held a certificate 
or diploma; while 8 % held a Masters’ degree. The average 
duration of service of the respondents in the health sec-
tor was 4.8 years.
Knowledge and views of participants on current treatment 
guidelines
Several respondents knew that the current recommended 
treatment for uncomplicated malaria is artemether–
lumefantrine for Plasmodium falciparum and chloro-
quine for Plasmodium vivax. Many participants knew 
that as injectable artesunate is the drug of choice for 
treatment of severe malaria.
On the other hand, a few respondents did not know the 
drug of choice for treatment of severe malaria cases. This 
lack of knowledge was found at both health centres and 
among health extension workers.
Quinine is a drug of choice for treatment of severe 
malaria. Injectable artesunate is given when a patient is 
not responding to quinine (Health centre staff, Oromia 
region).
Information on use of rectal artesunate as pre-referral 
treatment at community/health post level was limited 
with the many of the respondents indicating that patients 
with severe malaria should be treated in hospital and 
health centres.
Health workers practices around the use of intramuscular 
or intravenous artesunate
Both respondents from health centres and hospitals said 
that injectable artesunate is commonly administered in 
their health facility and the intravenous route was the 
most commonly cited route for the administration of 
treatment for severe malaria. However, one participant 
from one health centre said that ‘Intramuscular injection 
is a common route in her facility.’
Participants said that the ‘intramuscular route is an 
alternative route for administration of injectable artesu-
nate’. The most common sources of information stated by 
participants on intramuscular route of administration of 
injectable artesunate in descending order were: trainings, 
malaria case management guidelines, and fellow health 
workers.
Ninety-nine percent of the participants responded 
erroneously that ‘Gluteal muscle is the site of administra-
tion for adult patients’ and only a couple of respondents 
correctly responded that ‘the deltoid and/or ventrolateral 
muscles are preferred site for intramuscular artesunate.’
Benefits of using intramuscular artesunate
Although the respondents especially those working at 
hospitals and health centres stated that they use intrave-
nous artesunate, they noted that the intramuscular route 
is easier to administer.
Yes, intravenous needs cannula, but [for] intramuscu-
lar there is no need for cannula, simply dilute and give the 
dose (Health Centre staff, SNNPR).
The only challenges could be in getting the vein entry 
at one single shot [for intravenous] (Health Centre staff, 
SNNPR).
However, some participants thought intravenous 
artesunate is faster acting than intramuscular. Another 
benefit identified was that less intense training is required 
for health workers before they can rightly administer 
intramuscular artesunate.
Intramuscular artesunate is not used often because 
intramuscular action is slow when compared to the intra-
venous and also intramuscular artesunate causes pain 
(Health Centre staff, SNNPR).
Possible barriers to using intramuscular injection at post 
referral facilities
Participants stated that no challenges should be expected 
as intramuscular artesunate is already included in the 
treatment guideline at the health centre and hospital level 
but the confidence of using the intravenous route might 
affect the use of intramuscular injection.
…the prevailing skill and knowledge of health workers 
who have been using intravenous quinine for treatment of 
severe malaria may negatively influence the use of intra-
muscular artesunate. (Medical Doctor at hospital, Oro-
mia region).
Some participants also anticipated low usage of intra-
muscular artesunate for treatment of severe malaria 
because intravenous medication facilitates the adminis-
tration of other intravenous drugs.
If the patient was on open intravenous cannula for 
another purpose, we also use the intravenous route not to 
add another burden of intramuscular administration on 
the patient (District malaria focal person, SNNPR).
As I said, based on [the] patient’s condition we choose 
the route. If [the patient is] critical and need[s] additional 
management, we prefer intravenous route. Otherwise, 
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Intramuscular injections are better (Medical Doctor at 
District Hospital, SNNPR).
The participants expressed the opinion that quinine 
might continue to be used because of stock outs of inject-
able artesunate due to poor drug and supply management 
affecting the use of intramuscular artesunate. The health 
workers stated that client preference of intravenous route 
was also a barrier to the use of intramuscular injections.
Those clients who are admitted are not happy with 
intramuscular artesunate administration, so for patient 
satisfaction purpose we use intravenous artesunate. (Dis-
trict malaria focal person, Oromia).
Practicality of health extension workers providing 
care for severe malaria using intramuscular artesunate 
as definitive as well as pre‑referral treatment
Participants said that lower health facilities especially 
health posts are not in a position to treat severe malaria 
using intramuscular artesunate because of the national 
policy doesn’t support it, extension workers have limited 
knowledge and skills of managing severe malaria compli-
cations, there is limited availability of suitable facilities at 
the health post.
As lower level health facilities do not have inpatient 
beds and facilities; they cannot manage severe malaria 
patients. Since severe malaria is a complicated medical 
emergency, severe malaria cases should be referred to hos-
pitals. (District hospital staff, SNNPR).
…it is difficult for them because there may be other 
comorbidities which needs treatments like infusions. So 
admitting the patient, it may be difficult. (Zonal malaria 
focal person, Oromia region).
Respondents suggested that with adequate training, 
and provision of beds and other facilities health posts 
would be able to manage severe malaria with intramus-
cular artesunate if referral was not possible and would 
also be able to provide pre-referral treatment with intra-
muscular artesunate.
It is possible for me to treat because I already give vac-
cination and depo [family planning injection] which I did 
not know how to give before my education and training 
(health extension worker, Oromia region).
Benefits and risks of managing severe malaria 
with intramuscular artesunate at lower level facilities
Participants were concerned that health extension work-
ers would not be able to manage complications often 
associated with severe malaria.
If health extension workers manage patients with 
severe malaria, case fatalities of malaria will increase; 
intramuscular artesunate should only be provided as a 
pre-referral treatment at health post level (Participant, 
partner organization).
A few participants raised the potential risk of drug 
resistance due to irrational use of intramuscular artesu-
nate, as it could be used for uncomplicated malaria.
Community health care workers cannot administer 
intramuscular artesunate for the treatment of severe 
malaria because of their educational status. Parasite may 
adapt [to] the drug if not administered properly. (Health 
worker, Oromia region).
Some respondents thought that given the accessibility 
of health posts to the community would empower them 
to manage severe malaria with intramuscular artesunate 
and this would save lives if referral was not possible or if 
there were delays in getting care.
Health posts are near to the community which does 
not require transportation. If a patient gets sick at night, 
health posts are the nearest health facility to the commu-
nity, therefore allowing health post to treat severe malaria 
cases using intramuscular artesunate is advisable (Health 
centre staff, Oromia region).
I am very happy, because this particular area is highly 
malaria endemic, if patient go to Healthcentre, he/she 
may not get service rapidly because [the] Health centre 
serve[s] a lot of population, but we are serving small pop-
ulation so [it is] easy for us to serve kebele [village] popu-
lation (health extension worker, SNNPR).
Policy implications
Participants involved in policy advice reported that intra-
muscular artesunate is already included in the treatment 
guideline for use at hospital and health centre level. Some 
of participants indicated that health extension workers 
can use intramuscular artesunate as pre-referral treat-
ment, but not definitive treatment of severe malaria once 
trained. Malaria experts who formulate policy said it is 
possible to revise the national treatment guidelines to 
include intramuscular artesunate as pre-referral treat-




The key findings from this study are: (1) majority of par-
ticipants knew the contents of the current treatment 
guidelines for uncomplicated malaria and for severe 
malaria at hospital level and health centre level but many 
did not know about the use of rectal artesunate and intra-
muscular artesunate for pre-referral treatment; (2) pro-
vision of intramuscular artesunate as pre-referral and 
definitive treatment for severe malaria at health posts 
could be lifesaving in situations where referral is not pos-
sible; (3) with adequate training, and provision of facili-
ties including beds, health posts can provide injectable 
artesunate as pre-referral medication, however, there was 
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hesitation of using this as definitive treatment for severe 
malaria (4) health workers in health centres and hospitals 
prefer the intravenous route because it can be used for 
co-administration of other drugs but suggest that in the 
case of health extension workers the intramuscular route 
is easier; (5) the most common reasons cited for not sup-
porting the definitive management of severe malaria 
using intramuscular artesunate at community level 
were; lack of capacity to manage complications of severe 
malaria cases at lower level health facilities and Fear of 
irrational use of the drug. (6) Intramuscular artesunate is 
already included in the national policy for health centres 
and hospitals, but pre-referral intramuscular artesunate 
at health post level will require evidence on safety and 
feasibility before policy shift.
The study findings are discussed under the themes 
of the Bowen feasibility framework [24], i.e. demand, 
acceptability, practicality, and integration (Fig. 2).
Demand
Respondents felt that the provision of intramuscular 
artesunate as pre-referral but not definitive treatment 
for severe malaria at health posts could be lifesaving. 
Intramuscular artesunate has been shown to be highly 
effective in the management of severe malaria [20–22, 
25–28] and WHO recommends the use of intramuscular 
artesunate where possible as pre-referral treatment. This 
WHO recommendation together with the study find-
ings would effectively support the use of intra-muscular 
artesunate as pre-referral treatment at the health post, 
however, it was clear that this can only be possible with 
adequate training and with supporting evidence of safety 
and feasibility. Although evidence from trials of neonates 
with severe bacterial infection demonstrate that where 
referral is not possible, care provided near home can be 
life-saving [28], respondents in this study were not in 
agreement with health extension workers using intra-
muscular artesunate as definitive treatment citing the 
lack of knowledge to manage severe malaria complica-
tions as a limitation to this.
Acceptability
The health workers in this study were aware that the 
national malaria treatment guidelines recommend the 
use of intramuscular artesunate as definitive treatment 
at health centres and hospitals. However, many of the 
study participants were not aware of the WHO recom-
mendation to use intramuscular artesunate and rectal 
artesunate as pre-referral treatment even when the use 
of rectal artesunate as a pre-referral treatment is in the 
policy guidelines for Ethiopia.
The study also found that healthcare workers find 
it easier to administer injectable artesunate via the 
intramuscular route compared to the intravenous route. 
Given the need to find a vein and use a cannula to estab-
lish a line, it is clear why the healthcare workers find 
using the intramuscular route easier. Jin and others [29] 
report findings from a study comparing preference of 
administering different medication using different routes; 
looking at the intramuscular route versus the intravenous 
route and conclude that the preference varies from drug 
to drug. On the other hand, Ntuku and colleagues [30] in 
a study conducted in the Democratic Republic of Congo 
report that healthcare workers find use of intramuscu-
lar artesunate easier to administer than quinine which is 
similar to these study findings although no comparison 
was made with other drugs.
Lack of capacity to manage complications of severe 
malaria cases, and fear of irrational use of the drug were 
cited as reasons for not supporting the use of intramus-
cular artesunate as definitive treatment of severe malaria 
at the health post level. Concerns that health exten-
sion workers might use injectable artesunate to manage 
uncomplicated malaria or administer suboptimal doses 
are fears that need to be further explored. Little work 
has been done on the safety of injections provided by 
lay health workers [31]; most of the work is heavy on lay 
health workers providing injectable contraceptives and 
shows they can be safely delivered [32, 33]. It was rec-
ommended that operational research to further explore 
the safety, feasibility and efficacy of using intramuscu-
lar artesunate as definitive and pre-referral treatment be 
conducted to support use of intramuscular artesunate 
to manage severe malaria cases at the health post level 
especially in  situations when access to higher level care 
is difficult or impossible. These studies will provide evi-
dence for policy recommendations on the use of inject-
able artesunate at the health post level which is currently 
not supported by both the WHO and the Ethiopia policy 
guidelines.
Practicality
The study findings indicate that the respondents felt that 
using intramuscular artesunate as definitive treatment 
at the health-post may not be possible as management 
of severe malaria is beyond just providing the antima-
larial, but also included management of complications 
which the health extension workers may not be in posi-
tion to do. Although the proximity of the health post to 
the community, and the relative ease of administration 
of intramuscular artesunate were stated as points that 
may make it a potential option to be explored. Respond-
ents noted that introduction of intramuscular artesunate 
at the health post could be hindered by inadequate and 
unskilled health workers, lack of equipped facilities, and 
lack of knowledge among health post workers to manage 
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Fig. 2 Key areas of focus for feasibility studies and possible outcomes Adapted from Bowen et al. [24]
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complications resulting from severe malaria. Indeed, 
many of the respondents stated that with adequate train-
ing, health centre can provide definitive treatment for 
severe malaria using intramuscular artesunate, however, 
they suggested that health posts should only provide pre-
referral intramuscular artesunate and not definitive treat-
ment. The Ethiopia national malaria policy provides for 
definitive management of severe malaria using intramus-
cular artesunate at the health centre and hospital level 
but not the health post.
Many health workers believe the intravenous route 
provides flexibility to administer other injectable drugs 
for comorbidities, is less painful, and is convenient to the 
patient. Moreover, because of previous experience using 
the intravenous route to deliver quinine health workers 
maybe more inclined to favour intravenous over intra-
muscular delivery. Most respondents felt that the intra-
muscular route was easier to use than the intravenous 
route due to problems inserting the cannula. Health 
extension workers are unlikely to have the skill to use 
intravenous drugs but can be trained to use intramus-
cular drugs. Jin and others [29] argue that if the safety 
and efficacy of the two injection routes are equivalent, 
clinicians should pay attention to patient preference 
and pharmacoeconomics because patient preference 
will ensure optimal treatment adherence and ultimately 
improve patient experience or satisfaction, while pharma-
coeconomic concern will help alleviate nurse shortages 
and reduce overall health care costs. Given Ethiopian’s 
health services are highly resources constrained (in terms 
of supplies, personnel, space and other resources), the 
intramuscular route when possible provides a cost effi-
cient option from a public health point of view that may 
contribute to more equitable access to care although this 
was not extensively explored as part of this study.
Pre-referral intramuscular artesunate at health post 
level will require evidence on safety and feasibility before 
policy shift.
Integration
Integration is the extent to which an idea, programme, 
process or measure can be incorporated within an exist-
ing system. The study findings indicate that injectable 
artesunate is already widely in use at hospitals and some 
health centres, with intravenous being the most com-
monly used route. From an integration perspective, in 
order to clarify for health workers when to use the intra-
venous or intramuscular route a standard operating 
procedure should be developed on the use of injectable 
artesunate.
Antero-lateral aspect of the thigh muscle is the pre-
ferred site of intramuscular administration of artesunate 
[6], yet other sites which are no longer recommended 
were mentioned by most of the respondents. This indi-
cates the need for capacity building to ensure health 
workers know and use preferred safe sites for intramus-
cular administration.
Study limitations may include: (1) health facilities 
were selected purposively based on accessibility dur-
ing the study period. It is possible that respondents 
from these facilities might have different views com-
pared to those from areas that were inaccessible; (2) the 
interview guide was structured with questions on use of 
intramuscular artesunate by health extension workers 
before those related to use at the health centre level. This 
might have negatively influenced the way some respond-
ents answered questions related to use of intramuscular 
artesunate at the health centre level, if they held the view 
that health extension workers should not use injectable 
artesunate; (3) as in most qualitative studies, the results 
of this study may not be generalizable but may be trans-
ferable to similar settings; (4) translation from local lan-
guages to Amharic and then to English may have affected 
interpretation of the results to some extent.
Conclusion
Intramuscular artesunate is easier to administer, is 
widely used at hospitals, and is already in the national 
policy for use as definitive treatment at the health cen-
tre and hospital level in Ethiopia. From the perspective of 
health workers in this study, use of intramuscular artesu-
nate as pre-referral treatment of severe malaria cases 
at the health post is possible but dependent on training 
and availability of skilled workers. Use of intramuscular 
artesunate as definitive treatment at health posts was not 
supported due to lack of skills by the health extension 
workers to manage complications associated with severe 
malaria, and operational research to establish its feasibil-
ity, safety and efficacy of use of injectable artesunate as 
pre-referral and definitive treatments at the health post 
was recommended to guide any implementation of such 
an intervention.
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